XenoPort Announces Presentations at the American Academy of Neurology Meeting

Business Wirevia The Motley Fool
Updated

XenoPort Announces Presentations at the American Academy of Neurology Meeting

SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (NAS: XNPT) announced today that it will present the following posters at the 65th Annual Meeting of the American Academy of Neurology in San Diego, California:

AP (arbaclofen placarbil)
Spasticity

  • An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to Multiple Sclerosis
    Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT
    Poster #: P03.267

  • The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs and Requirement for Non-Professional Care: Results of a Cross-Sectional Study in the USA
    Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT
    Poster #: P03.217

  • Impact of Spasticity on Healthcare Resource Utilisation: Results of a Cross-Sectional Study in the USA
    Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT
    Poster #: P03.211


XP1279
Parkinson's Disease

  • Double-Blind Study of an Actively-Transported Levodopa Prodrug, XP21279, in Parkinson Disease
    Session Info: Poster Session P02: March 19, 7:30 am - 12:00 pm PT
    Poster #: P02.075

XP23829
Preclinical and Phase 1 Studies

  • Comparative Gastric Irritation of the Fumaric Acid Esters Dimethyl Fumarate (DMF) and XP23829 in Rat and Monkey
    Session Info: Poster Session P01: March 18, 2:00 pm - 6:30 pm PT
    Poster #: P01.159

  • Favorable Metabolism and Pharmacokinetics of Formulations of XP32829, a Novel Fumaric Acid Ester, in Healthy Subjects
    Session Info: Poster Session P05: March 20, 2:00 pm - 7:00 pm PT
    Poster #: P05.189

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended Release Tabletsis our first approved product in the United States. GlaxoSmithKline holds commercialization rights for Horizant in the United States during a transition period ending on April 30, 2013, following which XenoPort will be responsible for the further development, manufacturing and commercialization of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease, relapsing-remitting multiple sclerosis and/or psoriasis.

To learn more about XenoPort, please visit the web site at www.XenoPort.com.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

Source code: XNPT2C



XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

KEYWORDS: United States North America California

INDUSTRY KEYWORDS:

The article XenoPort Announces Presentations at the American Academy of Neurology Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement